TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Intracellular levels of branched-chain amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chronic GVHD (Grade II-IV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of early CMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety observation
Endpoint domain: Adverse events/effects
Primary endpoint: Composite primary outcome including sepsis, SIRS, thrombosis, organ failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects That Develop New, Active Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Success rate (loss of sensation to pinprick in the forearm and hand)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pH modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in local laboratory hemoglobin level from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Center of pressure displacements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil CD64 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sTREM-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fugl-Meyer Assessment (FMA) scores of the upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of rare or novel disease-causing genetic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of clinical features of novel and rare disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kilocalories delivered by enteral route
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Enteral nutrition-related mesenteric ischemia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in unstimulated whole mouth saliva flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: log10 IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4+ T-cell Activation Percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: log10 D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8+ T-cell Activation Percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in PTSD symptomatology (PCL-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PTSD symptomatology/diagnosis (CAPS-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of the hernia
Endpoint domain: Mortality/survival
Primary endpoint: ETV success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HI titers after 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HI titers after 3 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of recurrent and metastatic cancer
Endpoint domain: Mortality/survival
Primary endpoint: Change in Melasma Area and Severity Index (MASI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of circulating EPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak airway pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rate of ovarian failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Quality of Life and Patient Functionality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall symptoms (AEs; SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life Enjoyment & Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Employment of Closed-Loop communications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with plasma viral load <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year Freedom From PSA Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Patients Alive and Without Radiological and/or Clinical Progression
Endpoint domain: Mortality/survival
Primary endpoint: Intracranial pressure (ICP) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival without need of mechanical ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of successful tracheal extubation at day 14 since symptom onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Methotrexate levels in brain extracellular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and efficacy of the microdialysis catheter
Endpoint domain: Adverse events/effects
Primary endpoint: relative neural interoceptive response - heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: relative neural interoceptive response - stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Accuracy of medical thoracoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic role of the biological material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute bioavailability Fabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory Organization Test Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anesthesia count
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Microbial Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adherence to the Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop Out After the Intervention Period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Diet and Activity Recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast Cancer Awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in health components score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physiologic variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects from chemotherapy and endocrine therapy
Endpoint domain: Adverse events/effects
Primary endpoint: sustained improvement in working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Correlation Coefficient for Accuracy of Test Device vs Reference Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root Mean Square Error Accuracy Between CPM and Reference Device for Respiration Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Correlation Coefficient Between Reference Tidal Volume (TV) and Test Device Relative Tidal Volume (rTV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Identification of participants with abnormal SUDOSCAN scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety of the new compression device
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in BCVA (Best Corrected Visual Acuity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood plasma assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in post-inhalation percent-predicted FEF 25-75 (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Marked Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Pre-BD FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Assessment of tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Endothelial function as a surrogate marker for cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Insulin function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean (Peak) Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of exposure to chemical/toxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in keratometry/corneal topography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants hospitalized with a diagnosis of acute liver failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Curve of Deferasirox After a Dose of 35 mg/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-Life of Deferasirox
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance/Bioavailability of Deferasirox in Patients With Poor Response to Deferasirox Compared to Patients With Good Response After a Dose of 35 mg/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of specialist service recommending chemoprevention prescribing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Chemoprevention medication prescribing rates in primary care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cardiac function and structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: β-thromboglobulin (β-TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical pregnancy rate with fetal heart beat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Leakage rate at 6 months post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of UR (unwanted reactions)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to onset of UR
Endpoint domain: Adverse events/effects
Primary endpoint: Local tolerability (injection site inspection)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Distal Radius Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Median pain score on POD1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Off Medication UPDRS Part III, Motor Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: Estimated Mean Change of the Montreal Cognitive Assessment (MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Estimated Mean Change of the Trail Making Test (TMT) B-A
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Firing rate of the subthalamic neurons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Low frequency band
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High frequency band
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short term detrended fluctuation analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in RDQ scores for GERD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Geometric Mean Ratio (GMR) for Vaccine Lots A and B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Ratio (GMR) for Vaccine Lots B and C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Ratio (GMR) for Vaccine Lots A and C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leucine turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Histopathological examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to the dietary intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: trough concentration of sitagliptin and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measles case incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects Who Reached Seroprotection by Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of Subjects Who Seroconverted or Had a Significant Increase in Geometric Mean Titer by Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in the Seroprotection Rates by Visit (Vaccine With Adjuvant - Vaccine Without Adjuvant)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of clients experiencing moderate and severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in speech discrimination score in noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Screened for Hepatitis C
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: High Contrast/High Illumination Binocular Visual Acuity at Near
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis B surface antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)
Endpoint domain: Adverse events/effects
Primary endpoint: number of exosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of episodes of severe intraoperative hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients who do not undergo active treatment
Endpoint domain: Mortality/survival
Primary endpoint: Superficial cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parabasal cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac left ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of mood episodes and post treatment relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to First Generalized Pustular Psoriasis Flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ED revisits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Absolute change of glycosylated hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sacral Slope Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Profound neuromuscular blockade reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Feasibility of HEPPI program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of HEPPI program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of change in percent predicted forced vital capacity (ppFVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Text Input Speed at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in numerical pain rating scale (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of each molecular subtype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of targeted genetic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of clinical failure by day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LCN2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time to first request for postoperative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of intraocular infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: brachial artery endothelium-dependent flow-mediated dilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: quality of life/health status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: resources use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Correlation of pleural fluid glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Length of latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dento-alveolar changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrophysiological Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients Who Made an Appointment for Behavioral Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: changes in respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in saturation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum toxicity grade
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients experiencing grade 3-4 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of the interscalene muscular ridges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MVD Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity line change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity response category
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metastasis-free Survival (MFS)
Endpoint domain: Mortality/survival
Primary endpoint: Diabetes Foot Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Foot Self-care Behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Eating behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Cytogenetic Response (CCyR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage liver fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Morning blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morning post dialysis weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Remaining Seizure Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effectiveness of the quadrivalent vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Economic impact of the quadrivalent vaccine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients Who Are Free of Serious Treatment Related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Who Are Free of Breast Cancer in the Treated Breast
Endpoint domain: Mortality/survival
Primary endpoint: Degree of acupoint sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of coronary artery stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Canadian Cardiovascular Society angina pectoris classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence of diverticulitis and/or diverticular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUC of Megace 800mg/20mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes